Australian leader in rapid, point-of-care diagnostic technologies Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has teamed up with MedPro Associates to increase national contract sales coverage across the US health system, government and primary care markets.
Adoption of FebriDx in US
The collaboration is expected to increase awareness and uptake of FebriDx, embedding the product in the country’s health system.
“We are thrilled to be working alongside MedPro to bring our products to the US market,” Lumos CEO and MD Doug Ward said.
“Their familiarity with US healthcare markets coupled with their strong customer relationships and business development expertise makes them an excellent partner.”
MedPro will provide sales representation, training and in-servicing for Lumos’ innovative FebriDx, a rapid point-of-care test, which helps differentiate between bacterial and non-bacterial infections.
Strategically positioned
The MedPro team of more than 60 territory representatives will serve as an extension to the Lumos salesforce and will be strategically positioned across the country to increase FebriDx awareness and adoption.
Under the partnership, MedPro will provide customer lead generation, sales revenue and customer training for FebriDx.
This will have an immediate impact on Lumos' US footprint, increasing awareness of the FebriDx technology among healthcare providers.
MedPro’s reach into acute care encompasses both the US hospital environment and the federal government, including:
- Department of Defense;
- Veterans Affairs;
- Department of Health and Human Services – Indian Health Services; and
- Federal Bureau of Prisons hospitals.
The team will build relationships with decision-makers in these large organisations and drive successful product conversions.
In the non-acute care setting, MedPro will service physician offices, ambulatory surgery centres, skilled nursing facilities and home health agencies.
“We are thrilled to be working alongside the Lumos team and supporting their products across all major medical markets, as the partnership will undoubtedly help patients and caregivers alike with fast, accurate assessments of various conditions facing patients here in the USA,” MedPro CEO Bill Sparks said.